Dehydrocarteolol hydrochloride is a known impurity associated with carteolol hydrochloride, a non-selective beta-adrenergic antagonist prescribed to lower intraocular pressure in patients with glaucoma… Read more
Dehydrocarteolol hydrochloride is a known impurity associated with carteolol hydrochloride, a non-selective beta-adrenergic antagonist prescribed to lower intraocular pressure in patients with glaucoma or ocular hypertension. Pharmaceutical laboratories rely on accurate reference standards, including the impurities, metabolites, and stable isotope labelled compounds in this category, to support rigorous analytical testing, method validation, and quality control procedures. By utilizing these high-quality materials, researchers can perform precise impurity profiling and degradation studies, which are essential for ensuring the consistency and regulatory compliance of the active pharmaceutical ingredient throughout the drug development and manufacturing lifecycle. These analytical tools help scientists detect, identify, and quantify trace levels of related substances, ensuring the integrity and safety of the final pharmaceutical product.